



## ASX ANNOUNCEMENT

### **Lumos receives US\$767,800 FebriDx® order from PHASE Scientific**

**MELBOURNE, Australia (4 August 2026)** – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to announce that it has received a US\$767,800 FebriDx® purchase order from PHASE Scientific.

Product delivery will be fulfilled progressively between now and October 2026, with revenue recognised upon shipment.

This purchase order is the initial order associated with the US\$5.0 million prepayment milestone received by Lumos following the grant of CLIA waiver for FebriDx® by the U.S. FDA on 27 March 2026. The order satisfies part of the Year 1 minimum order quantity commitment under the distribution agreement with PHASE Scientific and will be credited against the prepayment, with the remaining prepayment balance available to support subsequent purchase orders.

Commenting on the announcement, Doug Ward, CEO and Managing Director of Lumos Diagnostics said: *“We are encouraged by the continued momentum as we advance the commercialisation of FebriDx®. This order comes at an important time as U.S. healthcare providers prepare for the upcoming flu season. We look forward to supporting the continued adoption of rapid, point-of-care acute respiratory infection testing across the U.S. market.”*

**-Ends-**

***This announcement has been approved by the Lumos Disclosure Committee.***

#### **About Lumos Diagnostics**

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit [lumosdiagnostics.com](http://lumosdiagnostics.com).

### **Forward-Looking Statements**

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

### **Media Contacts:**

Haley Chartres – Australia  
HACK Director  
[haley@hck.digital](mailto:haley@hck.digital)  
+61 423 139 163

### **Investor Contact:**

George Kopsiaftis  
IR Specialist, IR Department  
[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)  
+61 409 392 687

### **Company Registered Office:**

Lumos Diagnostics Holdings Ltd  
Suite 2, Level 11  
385 Bourke Street  
Melbourne VIC 3000  
[info@lumosdiagnostics.com](mailto:info@lumosdiagnostics.com)  
+61 3 9087 1598

For personal use only